Skip to content

EyePoint, Inc. EYPT EBITDA margin

EBITDA margin at other companies

Merck & Co. logo
Merck & Co.MRK
22.4%-12.4pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
27.9%-2.8pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-566.5%+1,247pp
HRO
HarrowHROW
8%+5.0pp
Theravance Biopharma logo
Theravance BiopharmaTBPH
2.7%+1.4pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-78.7%-2.1pp

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Calculated from EyePoint, Inc. ’s reported figures.

Based on trailing twelve months.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's EBITDA margin?
EyePoint, Inc. (EYPT) reported EBITDA margin of -3,668.2% in Q1 2026.
How has EyePoint, Inc. 's EBITDA margin changed year-over-year?
EyePoint, Inc. 's EBITDA margin decreased by 1187.1% year-over-year, from -285% to -3,668.2%.
What is the long-term trend for EyePoint, Inc. 's EBITDA margin?
Over 5 years (2020 to 2025), EyePoint, Inc. 's EBITDA margin has grown at a 50.2% compound annual growth rate (CAGR), from -100.6% to -768.5%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.